Page 2 - Diagnostics Inc News Today

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Shockwave Medical (NASDAQ:SWAV – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Volatility and Risk Lucid Diagnostics has a beta […]

Co-Diagnostics (NASDAQ:CODX – Get Free Report) and Biotricity (NASDAQ:BTCY – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk. Valuation and Earnings This table compares Co-Diagnostics and Biotricity’s […]

Co-Diagnostics (NASDAQ:CODX – Free Report) had its target price lowered by HC Wainwright from $2.50 to $2.00 in a research report report published on Monday, Benzinga reports. The firm currently has a neutral rating on the stock. HC Wainwright also issued estimates for Co-Diagnostics’ Q2 2024 earnings at ($0.34) EPS, Q3 2024 earnings at ($0.34) […]

Lucid Diagnostics Inc. (NASDAQ:LUCD – Free Report) – Investment analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Lucid Diagnostics in a report issued on Wednesday, May 15th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.06) per share for the year, down from their […]

Needham & Company LLC reaffirmed their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $2.50 price objective on the stock. Separately, Cantor Fitzgerald reduced their price target on shares of Lucid Diagnostics from $3.80 to $3.00 […]

Needham & Company LLC restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research report report published on Monday, Benzinga reports. Needham & Company LLC currently has a $2.50 price objective on the stock. Separately, Cantor Fitzgerald lowered their target price on shares of Lucid Diagnostics from $3.80 to […]

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Monday, May 13th. Individual interested in registering for the company’s earnings conference call can do so using this link. Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last released its quarterly earnings data on Tuesday, March […]

Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) is scheduled to release its earnings data after the market closes on Wednesday, May 8th. Analysts expect Accelerate Diagnostics to post earnings of ($0.72) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link. Accelerate Diagnostics (NASDAQ:AXDX […]

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is scheduled to announce its earnings results before the market opens on Monday, May 13th. Parties that are interested in registering for the company’s conference call can do so using this link. Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last posted its quarterly earnings data on Tuesday, March […]

/PRNewswire/ -- Last month a new utility patent, US Patent 11,953,501, was issued to LSU Health New Orleans for a noninvasive test called NECDetect that aids...